Cannabis and cannabinoids in dermatology: protocol for a systematic review and meta-analysis of quantitative outcomes

Following the discovery of various effects on skin function by modifying endocannabinoid systems, multiple preclinical studies have revealed the promise of cannabis and cannabinoids in the treatment of a variety of skin diseases. However, its clinical efficacy is still debated. This systematic review aims to evaluate the therapeutic efficacy of cannabis and cannabinoids in dermatological conditions and diseases. The protocol has been prepared using the Preferred Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines and has been registered with the International Prospective Register of Systematic Reviews (PROSPERO: CRD42023397189). PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science will be used for the systemic search. The outcomes will be an improvement in dermatological characteristics, including disease-specific composite scores and objective and subjective outcomes of skin conditions. This systematic review will provide valuable information on dermatological therapy of cannabis and cannabinoids and could be the start of future research and medicinal applications.

[1]  A. Chuklin,et al.  Prediction and diagnosis of chronic kidney disease development and progression using machine-learning: Protocol for a systematic review and meta-analysis of reporting standards and model performance , 2022, medRxiv.

[2]  Miri Kim,et al.  Skin Barrier Function and the Microbiome , 2022, International journal of molecular sciences.

[3]  C. Laezza,et al.  Cannabinoids: Therapeutic Use in Clinical Practice , 2022, International journal of molecular sciences.

[4]  N. Toyang,et al.  The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases , 2021, International journal of molecular sciences.

[5]  N. Emanuele,et al.  The effects of cannabis and cannabinoids on the endocrine system , 2021, Reviews in Endocrine and Metabolic Disorders.

[6]  K. Shao,et al.  Cannabis and the skin. , 2021, Clinics in dermatology.

[7]  D. Calina,et al.  Cannabinoids in the Pathophysiology of Skin Inflammation , 2020, Molecules.

[8]  B. Kaffenberger,et al.  Cannabinoids for the Treatment of Chronic Pruritus: A Review. , 2020, Journal of the American Academy of Dermatology.

[9]  A. Schlag.  An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK? , 2020, Medical Cannabis and Cannabinoids.

[10]  H. Chu,et al.  When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation , 2019, British Medical Journal.

[11]  Fatemeh Norooznezhad,et al.  Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation. , 2017, Medical hypotheses.

[12]  Rajiv Radhakrishnan,et al.  Marijuana Legalization: Impact on Physicians and Public Health. , 2016, Annual review of medicine.

[13]  S. Jeong,et al.  Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone‐induced atopic dermatitis model , 2015, International journal of dermatology.

[14]  E. Camera,et al.  Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. , 2014, Journal of Clinical Investigation.

[15]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[16]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[17]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[18]  E. Onaivi,et al.  Endocannabinoid System Components: Overview and Tissue Distribution. , 2019, Advances in experimental medicine and biology.

[19]  Franjo Grotenhermen,et al.  Pharmacokinetics and Pharmacodynamics of Cannabinoids , 2003, Clinical pharmacokinetics.